On the cusp of milestone TGA (Therapeutic Goods
Administration) authorization in Australia to start clinical trials in its
breakthrough Parkinson’s disease (PD) treatment using human parthenogenetic
neural stem cells (hpNSCs), International Stem Cell Corp. (OTCQB: ISCO) was
proud to show markets recently that the company has achieved a point of
maturity where it is also driving home steadily increasing revenues. The
release of the company’s Q2 2015 data also showed record net income for the
quarter, with outlays decreasing due to having successfully wrapped on a number
of important preclinical studies, even as revenues increased 14 percent year
over year, and profit margins held steady at around 72 percent.
The company’s increasingly lucrative biomedical business and
consistently profitable regenerative skin care offerings, administrated
respectively via ISCO’s wholly-owned Lifeline Cell Technology and Lifeline Skin
Care subsidiaries, continue to materially backstop the ongoing development of
an exciting therapeutic pipeline based on proprietary human parthenogenetic
stem cell (hpSC) technology which is efficient, perfect for commercial scale
volumes, and also completely ethical. ISCO’s parthenogenesis technology employs
a unique chemical stimulation technique for triggering unfertilized donor human
eggs to create pluripotent cells that can then be differentiated through
proprietary activation into numerous types of cells. From the aforementioned
hpNSCs, which are increasingly seen via the company’s trial work as a paradigm
shift approach when it comes to treating neurological system conditions like PD
and even ischemic stroke. To liver and eye cells that can be used to
effectively treat degenerative diseases affecting those tissue systems, such as
metabolic liver disease and macular degeneration.
Just looking at the company’s application of hpNSCs in PD,
we see a fundamentally new approach to therapy using transplanted stem cells,
which could actually solve the underlying problems that give rise to such
conditions, rather than just attempting to ameliorate the condition as with
many other therapies, including the current standards of care. In PD, where
injected hpNSCs actively differentiate into both dopaminergic neurons, as well
as express brain-protecting neurotrophic factors, and thus directly address the
two primary causes of debilitation, this approach shows its monumental
superiority to other approaches by simultaneously replacing dead neurons and
protecting any survivors. This kind of therapeutic solution constitutes an
end-run on PD, and potentially many other diseases/disorders via a completely
ethical, high-volume stem cell production technology, and it could make ISCO
into one of the now $27 billion plus global stem cell market’s heaviest
hitters.
Recent projections by Transparency Market Research indicate
that the global stem cell market is just getting warmed up too. With around 24
percent CAGR seen occurring through 2018 and valuations the following year of
as much as $119 billion or more, this highly fragmented market is primed for
explosive growth. Something which is especially true for real innovators like
ISCO, given that pluripotent stem cells are also seen as rapidly eclipsing the
core adult stem cell type that currently has around 80 percent of the market
share.
Perhaps even more importantly, the company’s UniStemCell
bank, which is effectively the life science industry’s first commercial-scale
aggregation of histocompatible, non-embryonic human stem cells, is ideally
positioned to benefit from the continued upswing in the sector. Providing a
growing logistical footprint of high-quality material for research purposes, as
well as commercial applications. Moreover, ISCO has established a solid
presence already here in the U.S., which is the epicenter of global activity
for the stem cell industry due to federal government support for the sector. As
the biobanking market expands further into Europe and other global markets, the
company will benefit from first-mover advantages.
To take a closer look, visit www.internationalstemcell.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
